Literature DB >> 33925140

IFN-γ Critically Enables the Intratumoural Infiltration of CXCR3+ CD8+ T Cells to Drive Squamous Cell Carcinoma Regression.

Zhen Zeng1, Margaret Veitch1, Gabrielle A Kelly1, Zewen K Tuong2, Jazmina G Cruz1, Ian H Frazer1, James W Wells1,3.   

Abstract

Ultraviolet (UV) radiation-induced tumours carry a high mutational load, are highly immunogenic, and often fail to grow when transplanted into normal, syngeneic mice. The aim of this study was to investigate factors critical for the immune-mediated rejection of cutaneous squamous cell carcinoma (SCC). In our rejection model, transplanted SCC establish and grow in mice immunosuppressed with tacrolimus. When tacrolimus is withdrawn, established SCC tumours subsequently undergo immune-mediated tumour rejection. Through the depletion of individual immune subsets at the time of tacrolimus withdrawal, we established a critical role for CD8+ T cells, but not CD4+ T cells, γδ T cells, or NK cells, in driving the regression of SCC. Regression was critically dependent on IFN-γ, although IFN-γ was not directly cytotoxic to SCC cells. IFN-γ-neutralisation abrogated SCC regression, significantly reduced CD8+ T cell-infiltration into SCC, and significantly impaired the secretion of CXCL9, CXCL10 and CCL5 within the tumour microenvironment. A strong positive correlation was revealed between CXCL10 expression and CD8+ T cell abundance in tumours. Indeed, blockade of the CXCL10 receptor CXCR3 at the time of tacrolimus withdrawal prevented CD8+ T cell infiltration and the regression of SCC. Chimeric models revealed an important role for immune cells as producers of IFN-γ, but not as recipients of IFN-γ signals via the IFN-γ receptor. Together, these findings suggest a key role for IFN-γ in driving the expression of chemokines within the tumour environment essential for the destruction of established SCC by CD8+ T cells.

Entities:  

Keywords:  CD8 T cell; IFN-γ; immune control; regression; squamous cell carcinoma

Year:  2021        PMID: 33925140     DOI: 10.3390/cancers13092131

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  41 in total

1.  Incidence of skin cancer in 5356 patients following organ transplantation.

Authors:  B Lindelöf; B Sigurgeirsson; H Gäbel; R S Stern
Journal:  Br J Dermatol       Date:  2000-09       Impact factor: 9.302

2.  Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.

Authors:  Hui Yi Chew; Priscila O De Lima; Jazmina L Gonzalez Cruz; Blerida Banushi; Godwins Echejoh; Lingbo Hu; Shannon R Joseph; Benedict Lum; James Rae; Jake S O'Donnell; Lilia Merida de Long; Satomi Okano; Brigid King; Rachael Barry; Davide Moi; Roberta Mazzieri; Ranjeny Thomas; Fernando Souza-Fonseca-Guimaraes; Matthew Foote; Adam McCluskey; Phillip J Robinson; Ian H Frazer; Nicholas A Saunders; Robert G Parton; Riccardo Dolcetti; Katharine Cuff; Jennifer H Martin; Benedict Panizza; Euan Walpole; James W Wells; Fiona Simpson
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

3.  Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin.

Authors:  Joerg Wenzel; Stefan Tomiuk; Sabine Zahn; Daniel Küsters; Anja Vahsen; Andreas Wiechert; Sandra Mikus; Michael Birth; Marina Scheler; Dagmar von Bubnoff; Jens M Baron; Hans F Merk; Cornelia Mauch; Thomas Krieg; Thomas Bieber; Andreas Bosio; Kay Hofmann; Thomas Tüting; Bettina Peters
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

4.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

5.  Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Authors:  Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

6.  Spleen cells from young but not old immunized mice eradicate large established cancers.

Authors:  Karin Schreiber; Ainhoa Arina; Boris Engels; Michael T Spiotto; John Sidney; Alessandro Sette; Theodore G Karrison; Ralph R Weichselbaum; Donald A Rowley; Hans Schreiber
Journal:  Clin Cancer Res       Date:  2012-03-13       Impact factor: 12.531

Review 7.  Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.

Authors:  Jennifer A Bridge; James C Lee; Adil Daud; James W Wells; Jeffrey A Bluestone
Journal:  Front Med (Lausanne)       Date:  2018-12-12

8.  Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.

Authors:  J L Urban; R C Burton; J M Holland; M L Kripke; H Schreiber
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

9.  Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab.

Authors:  Xuzhi He; Jazmina L Cruz; Shannon Joseph; Nicola Pett; Hui Yi Chew; Zewen K Tuong; Satomi Okano; Gabrielle Kelly; Margaret Veitch; Fiona Simpson; James W Wells
Journal:  Oncotarget       Date:  2018-01-13

10.  Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage.

Authors:  Zewen K Tuong; Andrew Lewandowski; Jennifer A Bridge; Jazmina L G Cruz; Miko Yamada; Duncan Lambie; Richard Lewandowski; Raymond J Steptoe; Graham R Leggatt; Fiona Simpson; Ian H Frazer; H Peter Soyer; James W Wells
Journal:  Sci Rep       Date:  2019-11-28       Impact factor: 4.379

View more
  1 in total

Review 1.  Cutaneous Squamous Cell Carcinoma Arising in Immunosuppressed Patients: A Systematic Review of Tumor Profiling Studies.

Authors:  Elliot D Blue; S Caleb Freeman; Marissa B Lobl; Dillon D Clarey; Rose L Fredrick; Ashley Wysong; Melodi Javid Whitley
Journal:  JID Innov       Date:  2022-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.